Front Row Advisors’s Molecular Templates, Inc. MTEM Stock Holding History

Front Row Advisors’s Portfolio MTEM Stock Details MTEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1	Closed	–	–	934
2023 Q2	$0	Hold	1	–	–	﹤0.01%	966
2023 Q1	$0	Buy	+1	New	+$7	﹤0.01%	968
2022 Q2	–	Sell	-1	Closed	–	–	958
2022 Q1	$0	Hold	1	–	–	﹤0.01%	966
2021 Q4	$0	Hold	1	–	–	﹤0.01%	970
2021 Q3	$0	Hold	1	–	–	﹤0.01%	964
2021 Q2	$0	Buy	+1	New	+$131	﹤0.01%	995
2021 Q1	–	Sell	-1	Closed	–	–	975
2020 Q4	$0	Hold	1	–	–	﹤0.01%	925
2020 Q3	$0	Hold	1	–	–	﹤0.01%	1034
2020 Q2	$0	Hold	1	–	–	﹤0.01%	1024
2020 Q1	$0	Hold	1	–	–	﹤0.01%	1063
2019 Q4	$0	Hold	1	–	–	﹤0.01%	955
2019 Q3	$0	Hold	1	–	–	﹤0.01%	1039
2019 Q2	$0	Hold	1	–	–	﹤0.01%	1087
2019 Q1	$0	Buy	+1	New	+$73	﹤0.01%	1111

Other funds holding MTEM

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Front Row Advisors's MTEM Position: Q3 2023 in Review

Front Row Advisors sold out of Molecular Templates, Inc. (MTEM) in Q3 2023, closing a stake of 1 share.

Front Row Advisors first reported a position in MTEM in Q1 2019 and held it in 14 quarters. The position peaked at $0 in Q2 2023. 30 funds tracked by Wall St. Rank hold MTEM as of Q3 2023.

Front Row Advisors reported no remaining Molecular Templates, Inc. position as of Q3 2023 after selling out during the quarter.
Front Row Advisors sold 1 Molecular Templates, Inc. share in Q3 2023.
Front Row Advisors first reported a position in Molecular Templates, Inc. in Q1 2019 and held it in 14 quarters.
Front Row Advisors's Molecular Templates, Inc. position peaked at $0 in Q2 2023.
30 funds tracked by Wall St. Rank held Molecular Templates, Inc. as of Q3 2023.

Based on Front Row Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.